Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
1.09
Dollar change
+0.04
Percentage change
3.81
%
Index- P/E- EPS (ttm)-1.72 Insider Own53.30% Shs Outstand43.96M Perf Week0.00%
Market Cap49.74M Forward P/E- EPS next Y-0.51 Insider Trans0.00% Shs Float20.53M Perf Month-15.50%
Income-62.80M PEG- EPS next Q-0.22 Inst Own16.09% Short Float0.20% Perf Quarter36.27%
Sales4.62M P/S10.77 EPS this Y58.99% Inst Trans4.09% Short Ratio0.17 Perf Half Y3.81%
Book/sh0.48 P/B2.28 EPS next Y55.56% ROA-82.36% Short Interest0.04M Perf Year23.85%
Cash/sh1.34 P/C0.81 EPS next 5Y- ROE-170.96% 52W Range0.49 - 1.93 Perf YTD98.18%
Dividend Est.- P/FCF- EPS past 5Y-44.91% ROI-222.41% 52W High-43.52% Beta-0.25
Dividend TTM- Quick Ratio1.67 Sales past 5Y0.00% Gross Margin62.40% 52W Low122.45% ATR (14)0.10
Dividend Ex-Date- Current Ratio1.67 EPS Y/Y TTM41.89% Oper. Margin-1388.44% RSI (14)55.42 Volatility6.43% 12.10%
Employees73 Debt/Eq0.40 Sales Y/Y TTM- Profit Margin-1359.37% Recom1.33 Target Price4.50
Option/ShortNo / Yes LT Debt/Eq0.35 EPS Q/Q63.70% Payout- Rel Volume0.26 Prev Close1.05
Sales Surprise-30.91% EPS Surprise10.82% Sales Q/Q- EarningsNov 07 BMO Avg Volume251.87K Price1.09
SMA208.35% SMA5013.23% SMA20014.12% Trades Volume65,989 Change3.81%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Dec-03-24 04:30PM
Nov-07-24 09:15AM
09:05AM
Oct-30-24 09:01AM
Oct-04-24 09:05AM
04:15PM Loading…
Oct-02-24 04:15PM
Aug-28-24 04:01PM
Aug-08-24 07:30AM
Jun-13-24 04:05PM
May-29-24 06:05AM
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
11:10AM Loading…
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
07:30AM Loading…
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08 '24Sale0.647334692,019,563Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08 '24Sale0.64267171734,546Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11 '24Sale0.871,5661,3622,021,836Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12 '24Sale0.831,5401,2782,020,296Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11 '24Sale0.87569495735,373Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12 '24Sale0.83560465734,813Jan 16 06:16 PM